Morgan Stanley raised the firm’s price target on Kymera Therapeutics (KYMR) to $73 from $70 and keeps an Overweight rating on the shares. Much of the attention on Kymera’s Q3 earnings call was centered around the upcoming Phase 1b atopic dermatitis readout expected in December, notes the analyst, who says Kymera reiterated confidence in KT-621.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Positive Outlook for Kymera Therapeutics Driven by Promising STAT6 Degrader Developments and Upcoming Data Release
- Kymera Therapeutics price target raised to $73 from $64 at Jefferies
- Kymera Therapeutics reports Q3 EPS (94c), consensus (79c)
- Kymera Therapeutics sees cash runway into 2H28
- Kymera Therapeutics assumed with a Buy at Guggenheim